Dranitsaris, George; Leung, Pauline; Ciotti, Renoto; … - In: PharmacoEconomics 19 (2001) 9, pp. 955-967
Background: The neurokinin-1 (NK1) receptor antagonists are a new class of agents designed to reduce the risk of emesis following chemotherapy, particularly with cisplatin. Early data from double-blind randomised trials suggest that an orally administered NK1 antagonist can reduce the absolute...